



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No. 55669-A-PCT-US  
Serial No. 09/753,169

INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

Applicant  
Cy A. Stein

Filing Date 01/02/01  
Group 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JR	AA 5 0 2 3 2 4 3	6/11/91	Tullis, R.			
	AB 5 1 0 7 0 6 5	4/21/92	Schewmaker, et al.			
	AC 5 4 9 6 5 4 7	3/96	Lam et al.			
	AD 5 5 8 7 4 7 0	12/24/96	Cook et al.			
	AE 5 5 9 3 9 7 4	1/97	Rosenberg et al.			
	AF 5 6 7 0 6 3 3	8/23/97	Cook et al.			
	AG 5 6 8 9 0 5 2	11/97	Brown et al.			
	AH 5 7 0 2 8 9 7	12/97	Reed et al.			
	AI 5 7 3 4 0 3 3	3/31/98	Reed et al.			
JR	AJ 5 7 7 6 9 0 5	7/98	Gibbons et al.			
	AK 5 8 4 3 7 1 3	12/98	Yoshida et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No
JR AL 9 8 0 5 7 7 7	02/98	WO			
JR AM 9 5 1 5 4 0 0	06/95	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JR	Agrawal, S., et al., Proc. Natl. Acad. Sci. U.S.A. (1988) Vol. 85:7079-7083;
	Antisense'97: A roundtable on the state of the industry. Nature Biotechnology 15(June 1997): 519-524;
JR	Beaucage, S., and Caruthers, M., Tetrahedron Lett. (1981) Vol. 22:1859-1862;

EXAMINER Janet E. Ford  
DATE CONSIDERED 6-12-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket  
No. 55669-  
A-PCT-USSerial No.  
09/753,169INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)Applicant  
Cy A. SteinFiling Date  
01/02/01Group  
/435

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*JS* Cook, P.D., "Medicinal Chemistry of Antisense Oligonucleotides - future opportunities" (1991) Anti Cancer Drug Design Vol. 6:585: -607;

Crooke, S.T. Vitravene--Another piece in the Mosaic. Antisense and Nucleic Acid Drug Dev. 8(1998):vii-viii.

Gewritz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on it s promise. Proc. Natl. Acad. Sci. USA 93 (April 1996); 3161-3163.

Ghosh, S., et al., J. Biol. Chem. (1990) Vol. 265:2935-2940

Gura, T. Antisense has growing pains. Science 270 (Oct. 1995): 575-577

Hemken, P., et al., J. Biol. Chem. (1992) Vol. 267:9948-0057;

Iverson, P., Anti-Cancer Drug Des. (1991) Vol. 6:531-538;

Krajewska, M. et al. "Immunohistochemical analysis bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancer." Am. J. Pathol. (1996) Vol. 148:1567-1576;

*JS* Luedeke, G.H., Ziegler, Al., Stahel, R.A., and Zangemeister-Wittke, U., "Antisense oligonucleotides targeting sequences shared by the Bcl-2 and the Bcl-xL mRNA efficiently downregulate expression of both proteins and induce apoptosis of lung cancer cells." Division

EXAMINER

DATE CONSIDERED

*Just Egu-Ford* 6-12-03  
\*EXAMINER Initial If reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 55669- A-PCT-US	Serial No. 09/753,169
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant Cy A. Stein	
				Filing Date 01/02/01	Group /635
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Ja		of Oncology, Department of Internal Medicine, University Hospital, CH-8091 Zurich, Switzerland. (Abstract #1140 from 88 Ann. Meet. AACR, April 12-16, 1997, Vol. 38, (March 1997), p. 171);			
		Milligan et al., "Current Concepts in Antisense Drug Design" Journal of Medicinal Chemistry (July 9, 1993) Vol. 36:1924-1937;			
		Pollman et al., "Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease." Nature Medicine (1998) Vol. 4:222-227;			
		Ratajczak, et al., Proc. Natl. Acad. Sci. U.S.A. (1992) Vol. 89:11823;			
		Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug delivery rev. 18(1996: 115-131.			
		Stein, C.A. Keeping the biotechnology of antisense in context. Nature Biotechnology 17(March 1999):209			
		Stull et al. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prosepcts. Pharm. Res. 12 (April 1995): 465-483.			
		Uhlmann, E. And Peyman A., "Antisense Oligonucleotides: A New Therapeutic Principle" Chem. Rev. (1990) Vol. 90:544-579;			
		Wang, Z. et al., "Induction of bcl-xl by CD40 Engagement Rescues slg-induced Apoptosis in Murine B Cells", The Journal of Immunology (1995) Vol. 155:3722-3725;			
EXAMINER	Curt E. Ford		DATE CONSIDERED 6-12-03		
*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant					



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket  
No. 55669-  
A-PCT-USSerial No.  
09/753,169INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)Applicant  
Cy A. SteinFiling Date  
01/02/01Group  
1635

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

*JK* Zhao, Q., et al., Antisense Research and Development (1993) Vol. 3:53-66;

*JK* Zon, G., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research (November 9, 1988) Vol. 5:539-549;

EXAMINER

DATE CONSIDERED

*Paul H. Egan, Fred* 6-12-03  
\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant